Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena Pharmaceuticals, a clinical-stage biopharmaceutical company, has started Phase 1 clinical trial evaluating APD916, a potent and selective inverse agonist of the histamine H3 receptor and an internally discovered drug candidate for the treatment of narcolepsy and cataplexy.
Subscribe to our email newsletter
Arena Pharma said that APD916 was efficacious in multiple preclinical models, and the data suggest that it has potential utility in the treatment of narcolepsy with or without cataplexy.
Reportedly, APD916 Phase1 trial is a randomised, double-blind and placebo-controlled trial. The company is planning to enroll up to 72 healthy adult volunteers and is expected to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD916.
William Shanahan, vice president and chief medical officer of Arena Pharma, said: “There is a need for better tolerated, more effective therapies for narcolepsy, especially narcolepsy with cataplexy. Based upon preclinical data, we believe that APD916 may substantially improve the treatment of these potential orphan indications.”